期刊
MOLECULES
卷 18, 期 6, 页码 6469-6490出版社
MDPI
DOI: 10.3390/molecules18066469
关键词
biomolecules; Cerenkov luminescence imaging; desferrioxamine B; dosimetry; positron emission tomography (PET); Zr-89
资金
- Fonds der Chemischen Industrie
Molecular imaging-and especially Positron Emission Tomography (PET)-is of increasing importance for the diagnosis of various diseases and thus is experiencing increasing dissemination. Consequently, there is a growing demand for appropriate PET tracers which allow for a specific accumulation in the target structure as well as its visualization and exhibit decay characteristics matching their in vivo pharmacokinetics. To meet this demand, the development of new targeting vectors as well as the use of uncommon radionuclides becomes increasingly important. Uncommon nuclides in this regard enable the utilization of various selectively accumulating bioactive molecules such as peptides, antibodies, their fragments, other proteins and artificial structures for PET imaging in personalized medicine. Among these radionuclides, Zr-89 (t(1/2) = 3.27 days and mean E beta+ = 0.389 MeV) has attracted increasing attention within the last years due to its favorably long half-life, which enables imaging at late time-points, being especially favorable in case of slowly-accumulating targeting vectors. This review outlines the recent developments in the field of Zr-89-labeled bioactive molecules, their potential and application in PET imaging and beyond, as well as remaining challenges.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据